Thursday 26th May 2016
Cytori Fully Enrols Pivotal US Phase III Scleroderma Trial
Cytori Therapeutics Inc. announces that its US FDA-approved phase III STAR trial has enrolled its 80th patient (100% of target enrolment). All 80 patients enrolled thus far in both trial arms have been successfully treated without complications. Full trial data are expected to be available in mid-2017.